Older adults see record increase in GLP-1 prescribing following Medicare GLP-1 Bridge program

July 2026 marked the largest month-to-month increase in GLP-1 prescribing among adults aged 65 years and older observed during the study period. AOM tirzepatide and AOM semaglutide showed the largest gains following launch of the Medicare GLP-1 Bridge, increasing 80.1% and 40.9%, respectively. Glucagon-like peptide-1 receptor agonists (GLP-1s) have transformed treatment for type 2 diabetes and obesity.